
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/">
  <dc:date>2013</dc:date>
  <dc:subject xml:lang="srp">OSNO - Opšta sistematizacija naučnih oblasti, Karcinogeneza</dc:subject>
  <dc:subject xml:lang="eng">OSNO - Opšta sistematizacija naučnih oblasti, Karcinogeneza</dc:subject>
  <dc:subject xml:lang="srp">molekularni tipovi karcinoma dojke, HER-2 i TOP2A genske aberacije,ER-R, PR-R, HER-2, TOP2A, BRCA1, p53, Bcl-2, Ki67 i ssDNA imunohistohemijska ekspresija</dc:subject>
  <dc:subject xml:lang="eng">molecular subtypes of breast cancer, HER-2 and TOP2A gene aberrations,ER-R, PR-R, HER-2, p53, Bcl-2, TOP2A, BRCA1, Ki67 and ssDNA expression</dc:subject>
  <dc:subject xml:lang="srp">576</dc:subject>
  <dc:rights>http://creativecommons.org/licenses/by-nc-nd/2.0/at/legalcode</dc:rights>
  <dc:format>PDF/A (189 listova)</dc:format>
  <dc:format>8615159 bytes</dc:format>
  <dc:title xml:lang="srp">Korelacija između proteinske i genske ekspresije HER-2 i topoizomeraze 2a kod infiltrativnog duktalnog karcinoma dojke  : doktorska disertacija</dc:title>
  <dc:contributor>Koko, Vesna, 1947-</dc:contributor>
  <dc:contributor>Čokić, Vladan, 1971-</dc:contributor>
  <dc:contributor>Budeč, Mirela, 1958-</dc:contributor>
  <dc:contributor>Markelić, Milica</dc:contributor>
  <dc:description xml:lang="srp">Uvod: Karcinom dojke predstavlja jako heterogeno oboljenje kao i jedno od
najzastupljenijih malignih bolesti u opštoj ženskoj populaciji. Na osnovu prisustva i
nivoa ekspresije ER-R, PR-R i HER-2 receptora ostvarena je podela na četiri
molekularna tipa karcinoma dojke: luminalni A (ER-R+ i / ili PR-R+, HER-2-), luminalni
B (ER-R+ i / ili PR-R+, HER-2+), HER-2 pozitivni (ER-R- i / ili PR-R-, HER-2+) i
trostruko negativni (ER-R- i / ili PR-R-, HER-2-) tip karcinoma dojke. U oko 20 do 30%
karcinoma dojke javlja se amplifikacija HER-2 i TOP2A gena. Amplifikacija HER-2 i
TOP2A gena je povezana sa lošijim ishodom bolesti, agresivnijim tokom i dobrim
odgovorom pacijentkinja na terapiju Herceptinom i antraciklinima. Koamplifikacija
HER-2 i TOP2A gena je prisutna u 12 do 38% karcinoma dojke. Na osnovu rezultata
nekoliko studija postavljena je hipoteza po kojoj se amplifikacija TOP2A gena javlja
isključivo sa amplifikacijom HER-2 gena, mada postoje i drugačija, suprotna mišljenja.
Cilj: Cilj naše studije bio je da se odrede genski statusi HER-2 i TOP2A kao i njihova
korelacija sa apoptotskim i proliferativnim indeksom, nivoom ekspresije ER-R, PR-R i
HER-2 receptora, TOP2A, BRCA1, Bcl-2 i p53 proteina, osnovnim kliničko-patološkim
parametrima kod tumora dojke 60 pacijentkinja podeljenih u četiri molekularna tipa.
Materijal i metode: Šezdeset tkivnih uzoraka karcinoma dojke ispitivano je
imunohistohemijskom metodom na prisustvo i stepen ekspresije ER-R, PR-R, HER-2,
p53, Bcl-2, TOP2A, BRCA1, ssDNA, Ki67, kao i FISH metodom na stepen genske
modifikacije HER-2 i TOP2A. Stepen modifikacije HER-2 i TOP2A gena analiziran je
primenom HER-2 FISH pharmDxTM kit i TOP2A FISH pharmDxTM kit
(DakoCytomation).
Rezultati:
Kliničko-patološki podaci - Starost ispitanica se kretala u rasponu izmeñu 38 i 87
godina (64.79 ± 21). Veličina tumora se kretala u opsegu izmeñu 0.4 i 5.5 cm, dok je histološki gradus G1 bio zastupljen kod 6 (10%) karcinoma, histološki gradus G2 kod
25 (41.7%) i histološki gradus G3 kod 17 (28.3%) karcinoma dojke...</dc:description>
  <dc:description xml:lang="eng">Introduction: Breast cancer is a heterogeneous disease and the most common
malignancy in women with increasing incidence in recent years. According to
immunohistochemical expression of estrogen receptor (ER-R), progesterone receptor
(PR-R) and HER-2 four different molecular subtypes of breast cancer were identified:
luminal A (ER-R+ and / or PR-R+, HER-2-), luminal B (ER-R+ and / or PR-R+, HER-
2+), HER-2 positive (ER-R- and / or PR-R-, HER-2+) and triple negative (ER-R- and / or
PR-R-, HER-2-) breast cancer subtypes. HER-2 and TOP2A genes are amplified in 20–
30 % of breast cancers. Amplification of HER-2 and TOP2A genes are associated with a
poor prognosis and predictive response to treatment by Herceptin and anthracycline.
Co-amplification of HER-2 and TOP2A has been seen in approximately 12–38 % of
patients with breast cancers. A few retrospective studies have reported that TOP2A gene
amplification occurs almost exclusively in conjunction with HER-2 gene amplification.
Aim: The aim of our study is to investigate HER-2 and TOP2A gene aberrations and
their correlation with apoptotic and proliferative indexes, Bcl-2, p53, ER-R, PR-R,
HER-2, TOP2A, BRCA1, clinicopathological parameters and overall survival in four
molecular subtypes of breast cancer.
Material and methods: Sixty paraffin-embedded breast cancer tissue samples were
studied immunohistochemically for the expression of ER-R, PR-R, HER-2, p53, Bcl-2,
ssDNA, Ki67, BRCA1, TOP2A and FISH for HER-2 and TOP2A gene aberrations.
HER-2 and TOP2A gene copy number were analyzed by HER-2 FISH pharmDxTM kit
and TOP2A FISH pharmDxTM kit (DakoCytomation), respectively.
Results:
Clinicopathological parameters - The ages of patients ranged from 38 to 87 years
(64.79 ± 21). The tumor size ranged between 0.4 and 5.5 cm, and the histological grades were G1, G2 and G3 in 6 (10 %), 25 (41.7 %), and 17 (28.3 %) patients, respectively. In
26 patients (43.4 %) lymph node status was negative; while in 22 patients (36.6 %) was
detected positive lymph node status...</dc:description>
  <dc:description xml:lang="srp">Biologija - Biologija ćelija i tkiva / Biology - Cell and Tissue Biology 
Datum odbrane : 01.11.2013 </dc:description>
  <dc:identifier>https://phaidrabg.bg.ac.rs/o:7287</dc:identifier>
  <dc:identifier>cobiss:44859407</dc:identifier>
  <dc:identifier>thesis:883</dc:identifier>
  <dc:type>info:eu-repo/semantics/bachelorThesis</dc:type>
  <dc:creator>Mitrović, Olivera S., 1979-</dc:creator>
  <dc:language>srp</dc:language>
</oai_dc:dc>
